Patents by Inventor Vandana Sood
Vandana Sood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160264971Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: ApplicationFiled: October 9, 2015Publication date: September 15, 2016Inventors: THOMAS W. GEISBERT, Amy C.H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Patent number: 9187748Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: GrantFiled: March 28, 2014Date of Patent: November 17, 2015Inventors: Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Publication number: 20150111945Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: ApplicationFiled: March 28, 2014Publication date: April 23, 2015Inventors: Thomas W. Geisbert, Amy C.H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Publication number: 20140161894Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.Type: ApplicationFiled: October 30, 2013Publication date: June 12, 2014Applicant: Alnylam Pharmaceuticals, Inc.Inventors: Ian MacLachlan, Adam Judge, Vandana Sood, James Heyes, Lloyd B. Jeffs, Lorne Palmer
-
Patent number: 8716464Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: GrantFiled: July 20, 2010Date of Patent: May 6, 2014Inventors: Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Patent number: 8598333Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.Type: GrantFiled: May 29, 2007Date of Patent: December 3, 2013Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Ian MacLachlan, Adam Judge, Vandana Sood, James Heyes, Lloyd B. Jeffs, Lorne Palmer
-
Patent number: 8455455Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target Lassa virus (LASV) or tissue factor (TF) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating hemorraghic fever).Type: GrantFiled: March 31, 2011Date of Patent: June 4, 2013Assignees: Protiva Biotherapeutics, Inc., The United States Army Medical Research and Materiel CommandInventors: Marjorie Robbins, Susan de Jong, Vandana Sood, Lisa E. Hensley, Ian MacLachlan
-
Patent number: 8188263Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: GrantFiled: January 23, 2009Date of Patent: May 29, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge, Amy C. H. Lee, Vandana Sood
-
Publication number: 20110201667Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: ApplicationFiled: July 20, 2010Publication date: August 18, 2011Applicants: Protiva Biotherapeutics, Inc., Trustees of Boston University, United States Army Medical Research and Materiel CommandInventors: Thomas W. Geisbert, Amy C.H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Publication number: 20110189300Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence ApoB expression and methods of using such nucleic acid-lipid particles to silence ApoB expression.Type: ApplicationFiled: May 20, 2010Publication date: August 4, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd B. Jeffs, Adam Judge, Amy C.H. Lee, Lorne R. Palmer, Vandana Sood
-
Publication number: 20110177131Abstract: The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.Type: ApplicationFiled: September 9, 2010Publication date: July 21, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Vandana Sood, Thomas W. Geisbert, Lisa E. Hensley, Elliott Kagan
-
Patent number: 7838658Abstract: The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.Type: GrantFiled: October 20, 2006Date of Patent: November 23, 2010Inventors: Ian MacLachlan, Vandana Sood, Thomas W. Geisbert, Lisa E. Hensley, Elliott Kagan
-
Publication number: 20090270481Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: ApplicationFiled: January 23, 2009Publication date: October 29, 2009Applicant: Protiva Biotherapeutics,Inc.Inventors: Ian MacLachlan, Adam Judge, Amy C.H. Lee, Vandana Sood
-
Publication number: 20090149403Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.Type: ApplicationFiled: May 29, 2007Publication date: June 11, 2009Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge, Vandana Sood, James Heyes, Lloyd B. Jeffs, Lorne Palmer
-
Publication number: 20070135370Abstract: The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.Type: ApplicationFiled: October 20, 2006Publication date: June 14, 2007Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Vandana Sood, Thomas Geisbert, Lisa Hensley, Elliott Kagan
-
Publication number: 20060134189Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence ApoB expression and methods of using such nucleic acid-lipid particles to silence ApoB expression.Type: ApplicationFiled: November 17, 2005Publication date: June 22, 2006Applicant: Protiva Biotherapeutics, IncInventors: Ian MacLachlan, Lloyd Jeffs, Adam Judge, Amy Lee, Lorne Palmer, Vandana Sood